Back to Research Hub
BridgeBio Pharma, Inc.
BBIO
$67.68+0.31 (+0.46%)
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development.
StreetsValue research for BridgeBio Pharma, Inc. (BBIO)
Members get the full report for BridgeBio Pharma, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.